Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan

Jyotsna Mehta, Hongwei Wang, Jon P. Fryzek, Sheikh Usman Iqbal, Ruben Mesa

Research output: Contribution to journalArticle

9 Scopus citations


Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) may lead to bone marrow fibrosis. Because the disease course of ET and PV are long and the disease course of MF may be fatal, healthcare resource utilization (HRU) associated costs of these neoplasms are especially important to understand. We used a large US health insurance claim database to describe the costs of these diseases. Compared to age-gender matched comparisons without myeloproliferative neoplasms (MPN), all aspects of HRU that we examined, including inpatient, outpatient and emergency room visits and pharmacy, as well as overall healthcare expenditures, were significantly higher in patients with MF, PV and ET (e.g. MF total costs = $54 168 vs. $10 203; PV = $14 903 vs. $7913; ET = $29 553 vs. $8026) than in matched comparisons. In order to reduce the burden of illness associated with these diseases, continued efforts in the development of more efficacious treatments for these disorders are needed.

Original languageEnglish (US)
Pages (from-to)2368-2374
Number of pages7
JournalLeukemia and Lymphoma
Issue number10
StatePublished - Oct 1 2014



  • Health resource utilization
  • Myeloproliferative disorders

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this